AZR — Azora Therapeutics Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 99.16 | ||
| Price to Tang. Book | 101.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -265.9% | ||
| Return on Equity | -2011.64% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Azora Therapeutics, Inc., formerly Adial Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. The Company is developing differentiated therapies for serious immune-mediated and inflammatory diseases. Its pipeline is AT177. AT177 is an investigational oral drug being developed for inflammatory bowel diseases, with an initial focus on ulcerative colitis. AT177 can deliver potent, colon-targeted Aryl-hydrocarbon Receptor (AhR) agonism directly to the site of disease. It is designed to capture the therapeutic benefits of AhR activation while minimizing systemic exposure. AT177's lead indication is in ulcerative colitis (UC), which is a chronic inflammatory disease of the colon and rectum. It is advancing AT177, a fully synthetic, patented, oral colon-targeted AhR agonist. The Aryl Hydrocarbon receptor (AhR) governs mucosal immunity and epithelial barrier integrity in the gut.
Directors
- J. Kermit Anderson IND (75)
- Robertson Gilliland IND (45)
- Kevin Schuyler NEC (56)
- Matthew Davidson PRE (42)
- Wendy Young DRC (60)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- October 5th, 2017
- Public Since
- July 27th, 2018
- No. of Shareholders
- 85
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 3,063,311
- Address
- 4870 Sadler Road, Suite 300, GLEN ALLEN, 23060
- Web
- https://azoratherapeutics.com
- Phone
- +1 8044878196
- Auditors
- Marcum LLP
Latest News for AZR
Upcoming Events for AZR
Q3 2026 Adial Pharmaceuticals Inc Earnings Release
Q4 2026 Adial Pharmaceuticals Inc Earnings Release
Similar to AZR
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 09:29 UTC, shares in Azora Therapeutics are trading at $4.00. This share price information is delayed by 15 minutes.
Shares in Azora Therapeutics last closed at $4.00 and the price had moved by -51.07% over the past 365 days. In terms of relative price strength the Azora Therapeutics share price has underperformed the S&P500 Index by -55.37% over the past year.
The overall consensus recommendation for Azora Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAzora Therapeutics does not currently pay a dividend.
Azora Therapeutics does not currently pay a dividend.
Azora Therapeutics does not currently pay a dividend.
To buy shares in Azora Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $4.00, shares in Azora Therapeutics had a market capitalisation of $15.47m.
Here are the trading details for Azora Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AZR
Based on an overall assessment of its quality, value and momentum Azora Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Azora Therapeutics is $8.51. That is 112.87% above the last closing price of $4.00.
Analysts covering Azora Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.93 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Azora Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +181.08%.
As of the last closing price of $4.00, shares in Azora Therapeutics were trading +58.62% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Azora Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Azora Therapeutics' management team is headed by:
- J. Kermit Anderson - IND
- Robertson Gilliland - IND
- Kevin Schuyler - NEC
- Matthew Davidson - PRE
- Wendy Young - DRC